Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Obinutuzumab in Patients With ISN/RPS 2003 Class III or IV Lupus Nephritis

Next Previous
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Obinutuzumab in Patients With ISN/RPS 2003 Class III or IV Lupus Nephritis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 29 Aug 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Obinutuzumab (Primary) ; Methylprednisolone; Mycophenolate mofetil; Mycophenolic acid; Prednisone
  • Indications Lupus nephritis
  • Focus Therapeutic Use
  • Acronyms NOBILITY
  • Sponsors Roche

Most Recent Events

  • 15 Nov 2023 Results assessing B-cell recovery after the last dose of obinutuzumab presented at the ACR Convergence 2023.
  • 15 Nov 2023 Results of post hoc analysis of NOBILITY assessing kidney-related outcomes and steroid-sparing effects, presented at the ACR Convergence 2023
  • 10 Nov 2023 Results of post hoc analysis of the phase II NOBILITY trial assessing whether adding obinutuzumab to standard-of-care lupus nephritis (LN) therapy could improve the likelihood of long-term preservation of kidney function and do so with less glucocorticoids published in the Arthritis and Rheumatology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top